血清肿瘤标志物组合模式在肺癌诊断中的评价  

Application value of serum tumor markers in diagnosis of lung cancer

作　　者：刘铁林[1] 孟凡超[1] 齐春华 

机构地区：[1]首都医科大学密云教学医院,北京101500 [2]北京密云县疾病预防控制中心,北京101500

出　　处：《中国卫生检验杂志》2014年第14期2022-2023,2026,共3页Chinese Journal of Health Laboratory Technology

摘　　要：目的评价4种肿瘤标志物在肺癌诊断中的应用价值。方法回顾性分析70例肺癌及配对的肺部良性疾病患者血清中癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、鳞状细胞癌相关抗原(SCC)的检测结果。结果与肺部良性疾病相比,肺癌患者CEA、CYFRA21-1、NSE、SCC血清水平及阳性率的差异均有统计学意义(P<0.05),但是四者对肺癌均不具备较高的诊断价值;CEA+CYFRA21-1+NSE组合用于诊断肺癌的灵敏度、正确率和Youden指数分别为90%、75%和0.50。结论建议将CEA+CYFRA21-1+NSE组合模式用于肺癌的实验室诊断。Objective To evaluate the application value of four tumor markers in diagnosis of lung cancer. Methods The test results of serum carcinoembryonic antigen （ CEA）, cytokeratin 19 fragment （ CYFRA21 - 1 ）, neuron specific enolase （NSE） and squamous cell carcinoma antigen （SCC） were retrospectively analyzed in 70 lung cancer eases and matched lung benign dis- ease patients. Results Compared with lung benign disease, the serum levels and positive rates of NSE, CEA, CYFRA21 - 1 and SCC in lung cancer had significant statistical difference（ P 〈 0.05 ）, but all the four tumor markers showed no higher diagnostic value for lung cancer by single detection. The sensitivity, accuracy and Youden index of combination of ＂CEA ＋ NSE ＋ CYFRA21 - 1＂ were 90%, 75% and 0.50 in diagnosis of lung cancer. Conclusion It is recommended that the combination of ＂CEA ＋ NSE ＋ CYFRA21 - 1＂ was used for laboratory diagnosis of lung cancer.

关 键 词：肿瘤标志物 肺癌 癌胚抗原 神经元特异性烯醇化酶 

分 类 号：R734.2[医药卫生—肿瘤]